Liver-specific expression of an exogenous gene controlled by human apolipoprotein A-I promoter

International Journal of Pharmaceutics
Yurong HuYun Zhang

Abstract

Liver-specific gene therapy is advantageous to minimize the possible adverse effects caused by non-target gene expression. The CMV promoter of the enhanced green fluorescent protein (EGFP) expressing plasmid pCMV-EGFP was replaced with the liver-specific promoter apolipoprotein A-I (ApoAI) generating pApoAI-EGFP plasmid. In vitro expression experiments performed in various cell lines including HepG2, SMMC-7721, MCF7, ACC-2 and Lo2 indicated that pCMV-EGFP treatment caused gene expression in all the cell lines, whereas pApoAI-EGFP treatment only induced EGFP expression in cells of liver origin including the liver cancer cells HepG2 and SMMC-7721 and the normal liver cells Lo2. Either pCMV-EGFP or pApoAI-EGFP was formulated as pegylated immuno-lipopolyplexes (PILP), a novel and efficient gene delivery system. Following intravenous administration of the PILP in H22 tumor-bearing mice, there was significant EGFP expression in liver, tumor, spleen, brain and lung in the pCMV-EGFP treated mice, whereas in the pApoAI-EGFP treated mice there was only gene expression in liver and tumor and the non-liver organ gene expression was eliminated. This study suggests that the use of the PILP technology and liver-specific promoter enables effic...Continue Reading

References

Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·S H ChenS L Woo
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P Venook
Oct 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·N ShiW M Pardridge
Feb 8, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yun ZhangWilliam M Pardridge
Jan 13, 2004·Methods in Enzymology·C Tros de IlarduyaN Düzgüneş
May 4, 2004·Annals of Medicine·Albert K GroenFolkert Kuipers
Oct 28, 2004·Gastroenterology·F Xavier BoschRamon Cléries
May 27, 2005·Seminars in Liver Disease·Lewis R Roberts, Gregory J Gores
Apr 13, 2007·Blood Cells, Molecules & Diseases·Alessia CalzolariUgo Testa
Feb 11, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yurong HuYun Zhang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Related Papers

Journal of Controlled Release : Official Journal of the Controlled Release Society
Yurong HuYun Zhang
Proceedings of the National Academy of Sciences of the United States of America
S H ChenS L Woo
The Journal of Pharmacology and Experimental Therapeutics
Yun Zhang, William M Pardridge
© 2021 Meta ULC. All rights reserved